Sanome
Sanome is a UK healthtech company that builds MEMORI, a Class IIb CE-certified and MHRA-registered AI clinical decision support tool embedded in hospital EPR systems to detect hospital-acquired infections up to 72 hours earlier, sold to NHS Trusts, private hospitals and EPR vendors.
- Company typePrivate
- Founded2022
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Sanome does
Sanome (legal entity: Human Digital Twin Ltd) is a UK-based healthtech company founded in 2022 and headquartered in London. It builds MEMORI, a Class IIb CE-certified, MHRA-registered AI Software-as-a-Medical Device that operates as a clinical decision support tool embedded directly inside hospital Electronic Patient Record (EPR) systems. MEMORI applies multimodal machine learning — combining structured data (vitals, lab results, medications) with unstructured free-text clinical notes via self-supervised pre-training and feature fusion — to flag emerging infection risk in secondary care patients up to 72 hours earlier than rule-based tools such as NEWS2. The model is supported by Sentinel, Sanome's MLOps and post-market surveillance platform, which handles bias, drift and model degradation monitoring, periodic re-training, and PMCF reporting.
The product is sold primarily to UK NHS Trusts and private hospitals under multi-year shared benefit / outcome-based agreements, with deployment via HL7v2 or FHIR integration into major EPRs (Epic, Cerner, Altera, PatientSource, MAXIMS, Luscii). Reference deployments include the Royal Hospital for Neuro-disability, East Kent Hospitals University NHS Foundation Trust, Leeds University Hospitals and Royal Devon University Hospitals. Sanome pursues a hybrid go-to-market combining a direct enterprise field sales motion (led by a dedicated Commercial VP) with an EPR/OEM channel-partner strategy that allows MEMORI to be embedded into partner EPR platforms. Revenue streams include subscription/outcome-based fees from Trust deployments, EPR partnership licensing, and non-dilutive grant income (most recently an Innovate UK SMART grant of over £300,000). The company is actively pursuing US FDA approval and expansion into Europe and the US, and is venture-backed by THENA Capital and Heal Capital.
Sanome firmographics
Firmographics- Name
- Sanome
- Legal name
- Human Digital Twin Ltd
- Website
- https://sanome.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sanome is a UK healthtech company that builds MEMORI, a Class IIb CE-certified and MHRA-registered AI clinical decision support tool embedded in hospital EPR systems to detect hospital-acquired infections up to 72 hours earlier, sold to NHS Trusts, private hospitals and EPR vendors.
- Ownership category
- akta.pro rank
Sanome industry classification
Industry- Product category
- Clinical Decision Support Software (AI SaMD)
- NAICS
- Software Publishers (513210)
- akta.pro primary industry
- Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)
- akta.pro secondary industry
- SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)
Keywords
Where Sanome is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Sanome business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Shared Benefit Agreement with NHS Trusts and Hospitals: Reimbursement model focused on ensuring the platform provides actual value to clinicians and patients; operates on a shared benefit agreement approach with Trusts and hospitals deploying MEMORI. Recurring revenue tied to deployment and outcomes.
- EPR Partnership / Embedded Licensing: MEMORI integrates into EPR partner platforms, enabling EPR providers to deliver AI-enabled decision support to their hospital customers. Revenue likely combines licensing/embedding with EPR partners.
- Grant Funding (Innovate UK SMART Grant): Received over £300,000 from Innovate UK to co-design MEMORI evolution. Non-recurring funding stream that supports R&D and validation, not core commercial revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Outcome Based/ Performance | Multi-year contract | Shared benefit agreement / outcome-based model with NHS Trusts and hospitals — pricing not publicly listed. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Sanome product offering
Product offeringCore offering
Sanome builds and sells MEMORI, a certified Class IIb AI Software as a Medical Device that runs as a Clinical Decision Support layer inside hospital Electronic Patient Record (EPR) systems. It ingests multimodal clinical data (vitals, lab results, medications, and free-text clinical notes) to surface emerging hospital-acquired infection risk up to 72 hours earlier than NEWS2, delivering explainable, guideline-aligned alerts directly within clinicians' existing workflows.
Product overview
Sanome's offering is a single regulated AI platform for secondary care hospitals, anchored by its core Class IIb-certified product MEMORI and supported by the Sentinel MLOps/Evidence Generation Framework. MEMORI is the certified AI-powered Clinical Decision Support tool embedded directly into a hospital's EPR that detects patient deterioration (notably hospital-acquired infections) up to 72 hours earlier than NEWS2, using multimodal AI over vitals, labs, medications and clinical notes to deliver explainable, guideline-aligned alerts within the clinician's existing workflow. Sentinel is the companion platform that powers MEMORI's continuous post-market surveillance — providing automated bias, drift and model degradation detection, periodic re-training and PMCF reporting — to keep MEMORI trusted, regulatory-compliant and outcomes-driven in live clinical use. Together, MEMORI (the certified clinical AI) and Sentinel (the MLOps backbone) form Sanome's product architecture.
Differentiator
Problem solved
Functional benefit
Brands
- MEMORI: Certified Class IIb AI-powered Clinical Decision Support tool embedded directly in hospital Electronic Patient Record (EPR) systems; detects emerging infection risk hours-to-days before clinical deterioration, with real-time patient risk stratification, consolidated data and trends, explainable AI, adjustable thresholds, and guideline-aligned recommendations.
- Sentinel
Products and services
- MEMORI MEMORI is Sanome's certified Class IIb AI-powered Clinical Decision Support tool embedded directly into a hospital's Electronic Patient Record (EPR). It continuously monitors patients using multimodal data (vitals, lab results, medications, clinical notes), surfaces emerging infection risk up to 72 hours earlier than NEWS2, and delivers explainable, guideline-aligned alerts and recommendations to clinicians within their existing workflow. Available cloud-hosted or on-premise, integrating via FHIR or HL7v2, and DCB0129/DTAC compliant.
- Sentinel Sentinel is Sanome's Evidence Generation Framework / MLOps platform that supports MEMORI in live clinical environments. It performs continuous post-market surveillance including automated bias detection, drift detection, model degradation monitoring, periodic re-training, and PMCF (post-market clinical follow-up) reporting to keep MEMORI trusted, regulatory-compliant, and outcomes-driven.
Quantifiable outcome
- Detect HAIs up to 72 hours earlier than current gold standard tools such as NEWS2
- +5 more outcomes
Companies that use Sanome
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Sanome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability7 records
Feature8 records
Sanome partnerships and signals
Strategic signalPartnerships
23 partnerships are on record, tiered core, flagship and minor.
- NIHR HealthTech Research Centre in Exeter (HRC in Sustainable Innovation)coreCo-development partner with Sanome on the Innovate UK SMART grant project to co-design the evolution of MEMORI and validate the platform across multiple wards at Royal Devon University NHS Foundation Trust; first impact data expected throughout 2026.
- Two UK Hospitals (unnamed in source)coreSanome announced two UK hospital partnerships to deploy its AI-powered clinical decision support platform MEMORI for earlier detection of hospital-acquired infections; the specific hospital names are not disclosed in the source.
- Lord James Bethell (Former UK Health Minister)coreJoined Sanome's strategic advisory board alongside Class IIb CE certification and MHRA approval; provides policy and frontline services expertise.
- Prof Carole Longson (former NICE Executive Director)coreJoined Sanome's strategic advisory board; brings HTA, market access and life sciences policy expertise from NICE and ABPI.
- Dr Arrash Yassaee (Deputy Director NHS England MedTech Innovation)coreJoined Sanome's strategic advisory board; provides NHS MedTech innovation and national policy perspective.
- Royal Hospital for Neuro-disability (RHN)flagshipReference deployment site for MEMORI. Customer evidence quotes show MEMORI cut morning handover huddle by 20 minutes, goes beyond NEWS2 with relevant advisories, and integrated seamlessly into the EPR. Matron Cameron Davey endorsed MEMORI as 'an angel on your shoulder.'
- East Kent Hospitals University NHS Foundation Trust (EKHUFT)coreUK NHS Trust partner; logo appears on Sanome's Partners page. Dr Michael Bedford of EKHUFT is listed as a co-author on Sanome's Clinical Co-Pilot whitepaper.
- Leeds University Hospitals (LUH)coreUK NHS Trust partner; logo featured on Sanome's hospital partner page alongside RHN, RDUH, EKHUFT and Altera.
- Royal Devon University Hospitals (RDUH)coreUK NHS Trust partner; logo displayed on Sanome's hospital partner page and serves as the validation site for the Innovate UK SMART grant project with NIHR HealthTech Research Centre.
- Epic SystemscoreEPR platform partner; Sanome positions MEMORI as embeddable within Epic and other leading EPRs via HL7v2 or FHIR interoperability standards, allowing hospitals to adopt AI decision support without disrupting existing workflows.
- Cerner (Oracle Health)coreEPR platform partner; Sanome promotes MEMORI integration with Cerner as part of its EPR channel proposition for AI-enabled secondary care.
- Altera Digital HealthcoreEPR partner listed on Sanome's Partners page; MEMORI integrates into Altera's hospital platform to deliver AI-enabled decision support to Altera's hospital customers.
- RSM (healthcare partner)minorListed as a partner on Sanome's Partners page (logo: RSM). Specific role is not described in the source.
- University of OxfordcoreDr Andrew Creagh (Sanome's AI/ML Lead) is affiliated with the University of Oxford, contributing research on remote patient monitoring and clinical decision support; Oxford also hosts Sanome's academic affiliations.
- University of KentminorDr Daniele Soria of the University of Kent is a co-author on Sanome's Clinical Co-Pilot whitepaper, signalling academic collaboration on clinical AI.
- Heal CapitalminorJustin Vibert of Heal Capital is a co-author on Sanome's Clinical Co-Pilot whitepaper; Heal Capital hosted the Heal Capital Day event featuring Sanome.
- CuristicaminorDr Keith Grimes of Curistica is a co-author on Sanome's Clinical Co-Pilot whitepaper, contributing clinical AI expertise.
- DebioPharmminorCedric Odje of DebioPharm is a co-author on Sanome's Clinical Co-Pilot whitepaper, indicating broader life-sciences ecosystem engagement.
- Dr Michelle TempestminorListed advisor on Sanome's About Us page; author of Big Brain Revolution: Artificial Intelligence – Spy or Saviour and AI expert.
- Pam Garside (Chair, Cambridge Angels)minorListed advisor on Sanome's About Us page; Chair of Cambridge Angels and leading expert advisor.
- Dr Alifa Isaacs-Itua (Consultant in Rehabilitation Medicine)minorListed clinical advisor on Sanome's About Us page; provides rehabilitation medicine expertise.
- Dr John Chinegwundoh (Consultant Respiratory Physician)minorListed clinical advisor on Sanome's About Us page; provides respiratory medicine expertise.
- Dr Veronica Choro-Mari (Consultant Pharmacist, Infectious Diseases)minorListed clinical advisor on Sanome's About Us page; provides infectious diseases and pharmacy expertise relevant to MEMORI's HAI detection focus.
Scale indicators11 records
Recent moves6 records
Expansion highlights7 records
Sanome competitors and assessment
Company assessmentBroad incumbents
- Oracle Health (Cerner): Major global EPR vendor and a Sanome channel partner. Comparable as an incumbent increasingly bundling native AI-driven deterioration and sepsis screening into its hospital platform.
- Wolters Kluwer (UpToDate / Sentri7): Provider of clinical decision support and surveillance tools (Sentri7) widely deployed in hospital systems. Comparable as an established CDSS incumbent that increasingly layers predictive analytics on top of EPR data — the same wedge MEMORI addresses.
- Epic Systems: Dominant US hospital EPR vendor and a Sanome channel partner. Comparable as the incumbent whose native deterioration/sepsis modules (e.g., Best Practice Advisories) compete directly with MEMORI at the workflow layer.
Direct peers
- Prenosis: FDA-authorised Sepsis ImmunoScore AI diagnostic for early sepsis detection in the ED/inpatient setting. Directly comparable to MEMORI as a regulated AI SaMD for infection prediction embedded in hospital workflows.
- Dascena (Inflammatix): Develops AI algorithms (originally Dascena's InSight) for early detection of sepsis and acute infection in hospitalised patients. Highly comparable to MEMORI's HAI/sepsis early-prediction use case on multimodal clinical data.
- Cytovale: Commercialises IntelliSep, an FDA-cleared cellular biomarker test for sepsis diagnosis in ED settings. Comparable as another infection/sepsis decision-support tool aiming to detect deterioration earlier than current standards.
- PeraHealth: Provides the Rothman Index, a continuous patient deterioration prediction score embedded into hospital EHR systems. Directly comparable to Sanome's MEMORI as an EPR-native AI early-warning platform for inpatient deterioration.
- Etiometry: AI clinical decision support platform for ICU patient deterioration and sepsis risk, integrating multiple physiologic data streams. Comparable to MEMORI in combining multimodal data with risk-stratification outputs for hospital clinicians.
Emerging players
- Huma: UK-headquartered digital health platform offering AI-driven remote patient monitoring and clinical decision support, deployed with NHS Trusts. Comparable as a UK-native regulated digital health platform targeting NHS secondary and remote care pathways.
- Luscii: Remote patient monitoring and virtual care platform deployed across European hospitals, listed as a Sanome integration partner. Comparable as an EPR-adjacent platform extending clinical decision support beyond the hospital wall.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Sanome social profiles
Digital presenceSanome compliance and trust
Trust signalCompliance10 records
Sanome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanome leadership team
Management profileNumber of profiles
Profiles9 records
Sanome funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanome
What does Sanome do?
Sanome builds and sells MEMORI, a certified Class IIb AI Software as a Medical Device that runs as a Clinical Decision Support layer inside hospital Electronic Patient Record (EPR) systems. It ingests multimodal clinical data (vitals, lab results, medications, and free-text clinical notes) to surface emerging hospital-acquired infection risk up to 72 hours earlier than NEWS2, delivering explainable, guideline-aligned alerts directly within clinicians' existing workflows.
Is Sanome a public or private company?
Sanome is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sanome founded?
Sanome was founded in 2022. It employs 11 to 50 people.
Where is Sanome based?
Sanome is headquartered in London, United Kingdom, in the Europe region.
How does Sanome make money?
Three revenue lines are on record. Shared Benefit Agreement with NHS Trusts and Hospitals are the primary driver. The others are EPR Partnership / Embedded Licensing and grant Funding (Innovate UK SMART Grant).
Who are Sanome's main competitors?
Broad incumbents on record are Oracle Health (Cerner), Wolters Kluwer (UpToDate / Sentri7) and Epic Systems. Direct peers are Prenosis, Dascena (Inflammatix), Cytovale, PeraHealth and Etiometry. Emerging players are Huma and Luscii.
Does Sanome have an API?
No public API is recorded for Sanome.
What industry is Sanome in?
Sanome's product category is Clinical Decision Support Software (AI SaMD). Its primary akta.pro industry code is HLACAGAF, Sepsis, Deterioration & Rapid Response CDS, with a secondary code of HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 513210.